American Innovation and R&D Competitiveness Act of 2025
Summary
HB1990, titled the American Innovation and R&D Competitiveness Act of 2025, would restore the immediate federal income tax deduction for research and experimental expenditures under section 174 of the Internal Revenue Code. The bill reverses the current requirement that many such costs be capitalized and amortized over time, allowing taxpayers to expense qualifying research and experimental costs in the year they are paid or incurred, subject to existing rules and limitations. It also preserves an optional amortization election for certain expenditures not deducted immediately.
The bill makes conforming changes to related provisions governing the research credit, including section 41 and the coordination rules in section 280C, so that the deduction and credit operate consistently. It applies retroactively to taxable years beginning after December 31, 2021, which would affect tax filings for years already closed or in process and could require amended returns or other administrative adjustments for some taxpayers. The measure is aimed at businesses and other taxpayers that incur domestic research and development costs, especially firms in technology, manufacturing, pharmaceuticals, and other innovation-intensive sectors.
The general sentiment reflected by the bill’s sponsorship is strongly supportive of restoring R&D expensing, with a large bipartisan group of House members listed as cosponsors. The title and structure of the bill indicate a pro-innovation, pro-competitiveness rationale, suggesting broad interest in reducing the tax burden on research investment and encouraging domestic development activity. No committee transcript or recorded vote is available in the provided materials, so there is no formal debate record here.
The main point of contention likely concerns fiscal cost and timing. Restoring immediate expensing would reduce near-term federal revenue relative to current law, and the retroactive effective date could create administrative and budgetary complications. Another potential issue is whether the change should be permanent, temporary, or paired with other tax offsets, as well as how the rule should interact with the research tax credit and with taxpayers that already capitalized and amortized costs under current law.
Impact
The bill would amend section 174 of the Internal Revenue Code to again allow taxpayers to deduct research and experimental expenditures as ordinary business expenses rather than amortizing them over multiple years. It would also update related provisions in sections 41 and 280C and the Code’s table of sections to conform to that change. The retroactive effective date would apply the amendments to taxable years beginning after December 31, 2021, potentially affecting prior returns and tax liability for affected businesses and other taxpayers.
Sentiment
The bill appears to have generally favorable bipartisan support, based on its many cosponsors from both parties and the policy goal of encouraging research and development investment. The framing of the measure emphasizes innovation, competitiveness, and relief from the current amortization regime. No votes or committee hearing statements were provided, so the available record does not show organized opposition in the materials, though the retroactive tax change and revenue effects are likely to draw scrutiny.
Contention
The likely areas of disagreement are the federal revenue loss from restoring immediate expensing, the retroactive application back to 2021, and the interaction between the deduction and the research credit. Supporters are likely to include innovation-focused lawmakers and business interests that want lower after-tax R&D costs, while critics may focus on budget impact, fairness to taxpayers who complied with current law, and whether the policy should be offset or limited. The bill also raises administrative questions for the IRS and taxpayers if prior-year returns must be amended or adjusted.
To Require Disclosure And Reporting Of Noncandidate Expenditures Pertaining To Appellate Judicial Elections; And To Adopt New Laws Concerning Appellate Judicial Campaigns.